



Docket No. 56495-2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: K. Donahue et al.

SERIAL NO.: 09/977,865

EXAMINER: K. Katcheves

FILED: October 15, 2001

GROUP: 1636

FOR: METHODS AND COMPOSITIONS FOR NUCLEIC ACID  
DELIVERY

#84B  
Hita  
7-14-03

RECEIVED

THE HONORABLE COMMISSIONER OF PATENTS AND TRADEMARKS  
WASHINGTON, DC 20231

JUL 09 2003

SIR:

TECH CENTER 1600/2900

AMENDMENT AND RESPONSE TO RESTRICTION REQUIREMENT

Applicants are in receipt of the Office Action dated June 3, 2003. Please amend the above-identified application as follows.

IN THE CLAIMS

Please add the following new claims.

70. The method of claim 1 wherein the tissue is treated with the phosphodiesterase inhibitor compound to increase vascular permeability.

71. The method of claim 1 wherein the phosphodiesterase inhibitor compound is a bicyclic heterocyclic compound.

72. The method of claim 1 wherein the phosphodiesterase inhibitor compound is a pyrazolo[4,3-d]pyrimidin-7-one, pyrazolo[3,4-d]pyrimidin-4-one, quinazolin-4-one, purin-6-one, or pyrido[3,2-d]pyrimidin-4-one.